Physicians' Academy for Cardiovascular Education

Emerging targets in HDL modification

Slides (presentation) - Oct. 18, 2011

Prof. John Kastelein
Academic Medical Centre
Amsterdam, The Netherlands 

To view presentation, click on slides below


Emerging targets in HDL modification: Relevant data from development programs
Novel Approaches to Modify Lipids and Lipoproteins
New Approaches for Raising HDL
The Verdict is Still Out on CETP Inhibition as a Mechanism
New Approaches for Raising HDL
Nicotinic AcidTreatment of Dyslipidemia and Atherosclerosis
ER Niacin Therapy
Effectiveness of 2 g vs 1 g of ER Niacin
Niacin Flushing Pathway: Two Separate Steps and Sites of Action
An Overview of the Niacin-Induced Flushing Pathway
Lipid/Flushing Study: Lower Incidence of Moderate or Greater Flushing vs ER Niacin
ER Niacin/Laropiprant Lipid Efficacy (Weeks 12-24)
Factorial Study: Lipid Efficacy
HPS2-THRIVE
New Approaches for Raising HDL
Where to Intervene in HDL-C Metabolism?
ApoA1 Based Therapies
ApoA-I is made in the Liver and Small Intestines.
RVX-208
RVX-208
Schematic of Phase 1a Protocol
Efficacy of RVX-208 in Humans
RVX208 α1-HDL Comparison vs. High Dose Statins α1-HDL
Cerenis HDL (CER-001) Homogeneous Drug Product
CER-001-CLIN-001 : 15 mg/kg LCAT Activation
CER-001 Mobilizes Cholesterol in Rabbits: Comparison with ETC-216
CHI SQUARE Study Design
CHI-SQUARE Study Design
CER-001-CLIN-001 Overall Conclusions
IVUS clinical trial using selective delipidated HDL
IVUS Clinical Trial Using Selective Delipidated HDL
Results of the IVUS Clinical Trial Using Selective Delipidated HDL
Conclusion
New Approaches for Raising HDL
LCAT Product Gradient Drives Reverse Cholesterol Transport
LCAT Deficiency in Humans
Impaired RCT in Familial LCAT Deficiency
Conclusion

Download teaching slides


Share this page with your colleagues and friends: